

**From:**

**Sent:**

**To:**

04 March 2021 12:43

**Subject:**

RE: Meeting of the Evaluation Committee with Novavax-

**Attachments:**

EC\_APA\_20210303Ad .docx

Dear Members of the Evaluation Committee,

Please find attached the latest version of the draft contract, including Novavax most recent .

will be discussed during the meeting this afternoon.

Kind regards,

---

**From:**

**Sent:** Tuesday, March 2, 2021 4:44 PM

**To:**

**Subject:** RE: Meeting of the Evaluation Committee with Novavax-

Dear Members of the Evaluation Committee,

Please find attached the comments sent yesterday to Novavax on the latest version of the draft contract.

It was explained to the company that, [REDACTED]  
[REDACTED] comments made are subject to clarifications on these fundamental elements.

Kind regards,

[REDACTED]

---

**From:** [REDACTED]  
**Sent:** Monday, March 1, 2021 2:48 PM  
**To:** [REDACTED]

**Subject:** Meeting of the Evaluation Committee with Novavax- [REDACTED]  
[REDACTED]

Dear Members of the Evaluation Committee,

Please note that a meeting of the Evaluation Committee with Novavax is scheduled for [REDACTED] [REDACTED]. A meeting invitation with the Webex details will be sent soon.

Kind regards,

[REDACTED]



European Commission  
DG SANTE  
[REDACTED]  
B-1040 Brussels/Belgium  
[REDACTED]

